الفهرس 
introductionيوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 364 |  |  |
| | | from | 364 | | |
المستخلص
The introduction contains more than 100 scientific references and includes a survey of studies on heterocyclic compounds containing thiophene or thiazole nuclei that have become more important in recent years due to their pharmacological properties. More than 90% of newly developed drugs have heterocyclic courses, placing most drugs in the category of heterogeneous organic compounds. Combining theofene or thiazole rings with various compounds containing various chemical reagents that enrich their biological activity. The main objective of this action is to synthesize some new heterocyclic organic compounds containing theofen or thiazole nuclei and evaluate their pharmacological activities to help detect more effective derivatives with lower toxicity in the future. The practical side of the study includes an accurate description of the different preparation methods that were used to obtain the chemical compounds that were prepared. It also includes spectral means (such as infrared, H1NMR, C13NMR and F19 NMR) used to create chemical structures of new heterocyclic organic compounds containing theofene or thiazole nuclei and evaluate their anticancer, antibacterial and antioxidant activity. For results and discussion: The strategic plan of our study began with the reaction of p-fluorophenacyl chloride (1) with various thiocarbamoyl compounds such as 2-acetyl-2-replacement-thiocytanilides, 3-arelazo-4- mercapto-4-phenilamine-buten-2-one, ethyl-2-arilazo-3-mercapto-3- phenilamineacrylate, N-aryl-2-cyano-3-mercapto-3-phenylaminoacrylamides, N-aryl-2- (mercapto (phenylamino) methylene)-3-oxobutanamides, and 2-mercapto-4,6-dimethylnicotinonitrile led to the production of new theofene compounds 4A-B, 7A-C, 10A-C and 13A-C, 16AC and 19. Furthermore, the reaction of 2-chlorosemide 23a, B derivatives with various nucleosulfur and/or nitrogen reagents (namely; mercaptoacetic acid, 2-mercaptopenzothiazole, 5-(phenilamine)-1,3,4-thiadiazole-2-thiol, 2- mercapto-4,6-dimethyl nicotinitrile, 3-arelazo-4-mercapto-4- (phenilamine)- bio-3-on-one derivatives, ammonium thiocyanate, piperidine and/or morpholin) resulted in the corresponding acetamide derivatives 23, 25, 27, 29, 30, 31, 35 and 37. Finally, the interaction of 3-oxobutanamidothiophene 38a, B derivatives with different nucleophile types such as 4- substitutedphenyl diazonium, different malononitrile arylidine, phenylisotthiocyanate in DMF/KOH to give the unisolated potassium salt that underwent in situ stirring with ethyl bromoacetate and methyl iodide resulted in new heterocyclic scaffolding 39-48. The antibacterial activity of newly formulated theofene compounds was tested using agar diffusion against gram-positive bacteria (B. subtilis & S. aureus) and gram-negative bacteria (E. coli and P. aeruginosa). The 3- hydroxythiophene 4a complex has shown good antibacterial property against S. aureus 87.5% and P. aeruginosa 86.9%, similar to the reference ampicillin. The antioxidant activities of newly formulated theophene-based compounds were evaluated using ABTS technology. Hydroxythiophene 4a boosted antioxidant activity to an inhibition level of 85.9%, which is very similar to the antioxidant reference L-Ascorbic acid (88.00%). The anti-cancer activity of newly formulated theofene compounds has been tested on the viability of two lines of human cancer cells: HepG2(hepatocellular carcinoma), and MCF-7 (breast cancer of the mammary gland). Compounds 23a, 23b, 31a and 31b showed the highest cytotoxic effect against the tested cell lines HepG2 and MCF-7, while compounds 43a and 43b showed the highest cytotoxic effect against one of the tested cell lines HepG2 (IC50 3 μM) IC50 values were higher than standard drug Anticancer Doxorubicin.